Balchem Q4 revenue beats on Human Nutrition and Health unit strength

Reuters02-20
Balchem Q4 revenue beats on Human Nutrition and Health unit strength

Overview

  • Nutritional ingredients maker's Q4 revenue rose 9.8%, beating analyst expectations

  • Adjusted EBITDA for Q4 grew 8.1% yr/yr, driven by segment sales growth

  • Company repurchased $53.6 mln of common stock during Q4

Outlook

  • Balchem did not provide specific financial guidance for 2026

Result Drivers

  • HUMAN NUTRITION GROWTH - Sales in the Human Nutrition and Health segment rose 12.7%, driven by higher demand in nutrients and food ingredients

  • ANIMAL NUTRITION GROWTH - Animal Nutrition and Health segment sales increased 4.9%, with growth in ruminant and monogastric species markets

  • SPECIALTY PRODUCTS GROWTH - Specialty Products segment sales rose 6.0%, attributed to higher sales in performance gases

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$263.60 mln

$259.59 mln (3 Analysts)

Q4 EPS

$1.21

Q4 Net Income

$39.20 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialty chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Balchem Corp is $191.00, about 9.1% above its February 19 closing price of $175.00

  • The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nGNX3tGdPt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment